Company intelligence / Profile preview

Pyxiscollege

Boston, Massachusetts, United Statespyxiscollege.be ↗

Ownership: Private
Development stage: Other

Overview

The company’s sole internal clinical asset is micvotabart pelidotin, an antibody-drug conjugate licensed from Pfizer. Phase 1 dose-escalation results in solid tumors showed encouraging safety and tolerability. No objective responses were reported for the discontinued monoclonal antibody PYX‑106 targeting Siglec‑15. The company is launching expansion trials of its ADC as monotherapy and in combination with pembrolizumab ("Keytruda") in head and neck squamous cell carcinoma, HR+/HER2– breast cancer, and triple-negative breast cancer.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateMonoclonal antibody
Industry: Biotech

Partnerships

Pfizer (in-license of ADC assets including PYX‑201)

Beyond the preview

Go deeper on Pyxiscollege.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pyxiscollege.

Explore the full profile